NovoCure (NASDAQ:NVCR) Receives Neutral Rating from Wedbush

NovoCure (NASDAQ:NVCR)‘s stock had its “neutral” rating reaffirmed by equities researchers at Wedbush in a report released on Thursday,Benzinga reports. They presently have a $18.00 target price on the medical equipment provider’s stock. Wedbush’s price target would indicate a potential upside of 30.72% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the stock. Evercore ISI set a $20.00 target price on shares of NovoCure in a research report on Monday, January 5th. JPMorgan Chase & Co. decreased their price objective on shares of NovoCure from $25.00 to $23.00 and set a “neutral” rating for the company in a report on Monday, October 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of NovoCure in a research note on Wednesday, October 8th. Finally, HC Wainwright lowered their price target on shares of NovoCure from $42.00 to $39.00 and set a “buy” rating on the stock in a report on Tuesday. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $25.50.

NovoCure Trading Up 0.9%

NVCR opened at $13.77 on Thursday. NovoCure has a fifty-two week low of $10.70 and a fifty-two week high of $27.70. The firm has a market capitalization of $1.54 billion, a PE ratio of -8.55 and a beta of 0.73. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.55 and a quick ratio of 1.50. The company’s 50-day moving average is $12.66 and its 200 day moving average is $13.22.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings data on Thursday, October 30th. The medical equipment provider reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.09. NovoCure had a negative return on equity of 50.29% and a negative net margin of 27.66%.The firm had revenue of $167.20 million during the quarter, compared to the consensus estimate of $158.81 million. During the same period in the prior year, the business posted ($0.28) earnings per share. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. As a group, research analysts predict that NovoCure will post -1.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in NVCR. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of NovoCure by 31.2% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 54,245 shares of the medical equipment provider’s stock worth $701,000 after buying an additional 12,915 shares in the last quarter. Exchange Traded Concepts LLC lifted its stake in NovoCure by 15.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 73,720 shares of the medical equipment provider’s stock worth $953,000 after purchasing an additional 9,621 shares in the last quarter. SG Americas Securities LLC grew its position in shares of NovoCure by 905.6% during the 4th quarter. SG Americas Securities LLC now owns 278,806 shares of the medical equipment provider’s stock valued at $3,605,000 after purchasing an additional 251,082 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its position in shares of NovoCure by 135.8% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 26,215 shares of the medical equipment provider’s stock valued at $375,000 after purchasing an additional 15,099 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of NovoCure by 104.2% during the third quarter. JPMorgan Chase & Co. now owns 282,184 shares of the medical equipment provider’s stock worth $3,646,000 after purchasing an additional 144,024 shares in the last quarter. Institutional investors own 84.61% of the company’s stock.

NovoCure News Roundup

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: HC Wainwright retained a “Buy” rating and set a $39 price target (reduced from $42), implying substantial upside from today’s price and likely supporting buying interest. Read More.
• Positive Sentiment: HC Wainwright published a long‑term outlook (FY2030 EPS of $3.28), signaling confidence in a recovery/outperformance over the next several years and giving investors a positive long‑term thesis to balance nearer‑term cuts. Read More.
• Neutral Sentiment: Management presented at the J.P. Morgan Healthcare Conference; the transcript provides operational and clinical updates that investors will parse for growth cadence and commercialization progress. Read More.
• Neutral Sentiment: Aggregate analyst coverage shows a mixed view — a recent report summarized a consensus rating around “Hold,” which may temper directional conviction despite pockets of bullishness. Read More.
• Negative Sentiment: HC Wainwright trimmed multiple near‑term and multi‑year EPS estimates (Q1–Q4 2026 and FY2026–FY2029), increasing expected losses in the near term (for example, FY2026 EPS was lowered to around -$1.49 from -$1.39). Those cuts weaken short‑term earnings visibility and are downside pressure for the stock. Read More.
• Negative Sentiment: A Seeking Alpha article questions NovoCure’s ability to disrupt non‑small cell lung cancer (NSCLC), highlighting clinical and market‑share challenges; negative narrative risk on therapy adoption could weigh on growth expectations if concerns persist. Read More.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.